Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low An OncLive® Scientific Interchange and Workshop

January 21st 2022

This article provides a summary of data on treatment approaches for HER2-positive breast cancer presented at conferences in 2021 and offers a review of how findings may affect clinical approaches to escalating or de-escalating therapy in patients with early-stage disease, optimally sequencing HER2-targeted therapy in patients with metastatic breast cancer, and selecting HER2-targeted agents based on the burden of CNS disease.

FDA Grants Fast Track Designation to Gedatolisib for Metastatic Breast Cancer

January 19th 2022

The FDA has granted a fast track designation to gedatolisib for use as a potential therapeutic option in patients with hormone receptor–positive, HER2-negative metastatic breast cancer who experienced disease progression on CDK4/6 therapy.

Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced Neutropenia

January 19th 2022

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

Question and Answer Session

January 19th 2022

Dr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.

FES-PET in the Treatment of Patients With Breast Cancer: Clinical Case 3

January 19th 2022

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

FES-PET in the Treatment of Patients with Breast Cancer: Clinical Case 2

January 19th 2022

Dr Jeremy Force illustrates how FES-PET aids in the treatment of patients with breast cancer through a clinical case.

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

January 18th 2022

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBC

January 13th 2022

Haythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.

FES-PET in the Care of Patients With Breast Cancer: Clinical Case 1

January 12th 2022

Dr Jeremy Force illustrates how FES-PET aids in the care of patients with breast cancer through a clinical case.

Is There a Role for FES-PET Imaging in Assessing ER Status and Extent?

January 12th 2022

A comprehensive analysis of the potential role of FES-PET imaging in assessing ER status in tumors that are difficult to biopsy and in evaluating the extent of disease.

Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast Cancer

January 11th 2022

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

FDA Grants Fast Track Designation to Enobosarm for AR+/ER+ Metastatic Breast Cancer

January 10th 2022

The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6 inhibitor, and who have AR staining of 40% or more in cancer tissue.

Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

January 7th 2022

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.

Dietz Draws Attention to Gender Disparities in Breast Cancer

January 6th 2022

Dr Dietz discusses her experience as a woman in surgical oncology, the importance of bridging gender disparities, and her advice to women entering the health care industry.

Developments With Immunotherapy, Maintenance Therapy, and Novel Strategies Push the Field of Women’s Cancers Forward

January 6th 2022

Melissa Geller, MD, MS, and colleagues discuss key clinical trials that have changed the landscapes of HER2-positive breast cancer and triple-negative breast cancer, the role of first- and second-line maintenance therapy in ovarian cancer, and key updates in cervical and endometrial cancers.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

January 5th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Dr. Tolaney on the Importance of Evaluating Enobosarm in ER+ Breast Cancer

January 5th 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

Applications of FES-PET Imaging in Breast Cancer Treatment Decision-Making

January 5th 2022

Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.

Role of FDG-PET Vs FES-PET in ER+ Breast Cancer

January 5th 2022

Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.